Malignant Mesothelioma (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma – Drugs In Development, 2021, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 53, 55, 2, 39, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 6, 4, 1 and 9 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

– The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AbbVie Inc

ADC Therapeutics SA

ADCendo ApS

Adienne Pharma & Biotech SA

AGC Biologics SpA

Akeso Inc

Aldeyra Therapeutics Inc

Alligator Bioscience AB

Almac Discovery Ltd

Amgen Inc

Amphera BV

AnGes Inc

Apollomics Inc

Applied Research using OMIC Sciences SL

Arch Oncology Inc

Ares Immunotherapy Inc

Table of Contents

Table of Contents

Introduction

Malignant Mesothelioma - Overview

Malignant Mesothelioma - Therapeutics Development

Malignant Mesothelioma - Therapeutics Assessment

Malignant Mesothelioma - Companies Involved in Therapeutics Development

Malignant Mesothelioma - Drug Profiles

Malignant Mesothelioma - Dormant Projects

Malignant Mesothelioma - Discontinued Products

Malignant Mesothelioma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Malignant Mesothelioma, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Malignant Mesothelioma – Pipeline by AbbVie Inc, 2021

Malignant Mesothelioma – Pipeline by ADC Therapeutics SA, 2021

Malignant Mesothelioma – Pipeline by ADCendo ApS, 2021

Malignant Mesothelioma – Pipeline by Adienne Pharma & Biotech SA, 2021

Malignant Mesothelioma – Pipeline by AGC Biologics SpA, 2021

Malignant Mesothelioma – Pipeline by Akeso Inc, 2021

Malignant Mesothelioma – Pipeline by Aldeyra Therapeutics Inc, 2021

Malignant Mesothelioma – Pipeline by Alligator Bioscience AB, 2021

Malignant Mesothelioma – Pipeline by Almac Discovery Ltd, 2021

Malignant Mesothelioma – Dormant Projects, 2021

Malignant Mesothelioma – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Malignant Mesothelioma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports